左氧氟沙星联合哌拉西林钠/他唑巴坦钠对支气管扩张症铜绿假单胞菌急性感染者的疗效评估

目的 探讨左氧氟沙星联合哌拉西林钠/他唑巴坦钠对支气管扩张症铜绿假单胞菌急性感染者的疗效及其经济影响。方法 选取60例支气管扩张症铜绿假单胞菌（非耐药）急性感染患者，随机分为3组，每组20例。其中A组予以左氧氟沙星治疗，B组予以哌拉西林钠/他唑巴钠治疗，C组予以左氧氟沙星联合哌拉西林钠/他唑巴钠治疗，疗程均为14 d。比较3组患者临床疗效、生理指标及抗菌药物治疗费用等。结果 治疗后，A、B和C组患者的临床总有效率分别为85.0%、90.0%、95.0%，差异均无统计学意义（χ2=0.5556、0.1802，P>0.05）。3组患者主要生理指标均有所改善，与治疗前比较差异均有统计学意义（P0.05）。C组患者抗菌药物治疗费用最高，与A、B组比较，差异均有统计学意义（t=36.8448、13.8504，P<0.05）；A组患者抗菌药物治疗费最低，与B组比较差异有统计学意义（t=28.1640，P<0.05）。结论 左氧氟沙星、哌拉西林钠/他唑巴坦钠均可用于治疗支气管扩张症铜绿假单胞菌急性感染，药物联用治疗无明显优势，且治疗费用显著增高。

Efficacy of Levofloxacin combined with Piperacillin/Tazobactam in the treatment of bronchiectasis patients with acute Pseudomonas aeruginosa infection

Objective To investigate the efficacy and economic benefits of Levofloxacin combined with Piperacillin/Tazobactam in patients with acute bronchiectasis and Pseudomonas aeruginosa infection. Methods 60 cases of bronchiectasis with acute Pseudomonas aeruginosa (non-drug resistant) infection were randomly divided into 3 groups, 20 cases in each group. The group A was treated with Levofloxacin, the group B was treated with Piperacillin/Tazobactam, while the group C was treated with Levofloxacin combined with Piperacillin/Tazobactam. Results The total clinical efficiency rate was 85.0% in group A, 90.0% in group B and 95.0% in group C, respectively. There was no significant difference among the 3 groups (χ2=0.5556, 0.1802; P>0.05). After treatment, the main physiological indexes in the 3 groups were improved (P0.05). The cost of drugs in group C was the highest and significantly different from those in the other two groups (t=36.8448, 13.8504; P<0.05). The cost of drugs in group A was the lowest, and significantly different from that in group B (t=28.1640, P<0.05). Conclusion Levofloxacin and Piperacillin/Tazobactam can be used to treat acute Pseudomonas aeruginosa infection in patients with bronchiectasis. The combined administration regimen has no obvious advantage, and the cost of treatment is high.